More than 55 million people around the world are living with dementia, and 60 to 80 percent of those cases are attributed to Alzheimer’s disease. There is currently no cure, but Yale researchers, led by Stephen Strittmatter and Lauren Sansing, aim to advance research in this critical area. Strittmatter and Sansing are co-directors of the new Carol and Gene Ludwig Program for the Study of Neuroimmune Interactions in Dementia, recently established with a gift from the Carol and Gene Ludwig Family Foundation.
The program brings together neuroscientists and immunobiologists across departments to advance innovative research and drive biomedical progress, therapeutics, and cures focused on combatting Alzheimer’s disease and related dementias.
Read more about the Ludwig Program at Yale School of Medicine.